VV116 versus Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19.

Zhu Jun CaoWeiyi GaoHong BaoHaiyan FengShuya MeiPeizhan ChenYueqiu GaoZhilei CuiQin ZhangXianmin MengHonglian GuiWeijing WangYimei JiangZijia SongYiqing ShiJing SunYifei ZhangQing XieYiping XuGuang NingYuan GaoRen Zhao

Published in: The New England journal of medicine (2022)

Among adults with mild-to-moderate Covid-19 who were at risk for progression, VV116 was noninferior to nirmatrelvir-ritonavir with respect to the time to sustained clinical recovery, with fewer safety concerns. (Funded by Vigonvita Life Sciences and others; ClinicalTrials.gov number, NCT05341609; Chinese Clinical Trial Registry number, ChiCTR2200057856.).

Keyphrases

coronavirus disease
sars cov
clinical trial
antiretroviral therapy
respiratory syndrome coronavirus
phase ii
open label
combination therapy
double blind
replacement therapy